中信证券股份有限公司 1 二、本次发行情况概述 关于深圳惠泰医疗器械股份有限公司 持续督导保荐总结报告书 | | | 2021 年 1 月 7 日，深圳惠泰医疗器械股份有限公司（以下简称"惠泰医疗" 或"公司"）在上海证券交易所上市。根据《中华人民共和国证券法》、《证券 发行上市保荐业务管理办法》、《上海证券交易所股票上市规则》等有关法律法 规的规定以及与惠泰医疗签订的保荐承销协议，中信证券股份有限公司（以下简 称"中信证券"或"保荐人"）作为保荐人，对惠泰医疗进行持续督导，持续督 导期为 2021 年 1 月 7 日至 2024 年 12 月 31 日。 截至目前，中信证券对惠泰医疗的持续督导期已满，根据《证券发行上市保 荐业务管理办法》和《上海证券交易所上市公司自律监管指引第 11 号——持续 督导》（以下简称"《持续督导工作指引》"）等相关规定，出具本保荐总结报 告书： | 公司名称 | 深圳惠泰医疗器械股份有限公司 | | | --- | --- | --- | | 证券代码 | 688617 | | | 注册资本 | 9708.1956 万元人民币 | | | 注册地址 | 深圳市南山区西丽街道松坪 ...

中信证券股份有限公司 关于深圳惠泰医疗器械股份有限公司 2024 年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为深圳惠 泰医疗器械股份有限公司（以下简称"惠泰医疗"或"公司"）首次公开发行股 票并在科创板上市项目的保荐人，根据《证券发行上市保荐业务管理办法》、《上 海证券交易所科创板股票上市规则》等相关规定，负责惠泰医疗上市后的持续督 导工作，并出具本持续督导年度跟踪报告。 一、持续督导工作情况 | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度， | 保荐人已建立健全并有效执行了持续督 | | | 并针对具体的持续督导工作制定相应的 | | | | 工作计划。 | 导制度，并制定了相应的工作计划。 | | | 根据中国证监会相关规定，在持续督导工 | | | 2 | 作开始前，与上市公司签署持续督导协 | 保荐人已与惠泰医疗签订承销及保荐协 | | | | 议，该协议明确了双方在持续督导期间的 | | | 议，明确双方在持续督导期间的权利义 | 权利和义务，并报上海证券交易所备案。 | | | ...

Summary of the Conference Call Industry Focus - The report focuses on the pharmaceutical industry, specifically highlighting innovative drugs and contract research organizations (CXO) Core Insights and Arguments - Continuous recommendation of innovative drugs with positive growth outlook, including: - 恒瑞医药 (Hengrui Medicine) - 华东医药 (East China Pharmaceutical) - 翰森制药 (Hansoh Pharmaceutical) - 贝达药业 (Betta Pharmaceuticals) - 信立泰 (Sinopharm) - 科伦药业 (Kelun Pharmaceutical) - 百利天恒 (Baili Tianheng) - 荣昌生物 (Rongchang Biopharmaceutical) - 科伦博泰生物 (Kelun Biotech) - 石药集团 (Shijiazhuang Pharmaceutical Group) [1][1][1] - Recommendation of CXOs showing signs of profit growth turning points, including: - 药明生物 (WuXi Biologics) - 药明康德 (WuXi AppTec) [1][1] - Positive outlook on domestic replacement of innovative medical devices, specifically: - 惠泰医疗 (Huitai Medical) [1] - Anticipation of recovery in consumer healthcare, particularly: - 爱尔眼科 (Aier Eye Hospital) [1] Other Important Points - The report emphasizes the ongoing trend of recommending companies that are positioned well within the pharmaceutical sector, particularly those that are expected to benefit from market dynamics and growth opportunities - The focus on innovative drugs and CXOs indicates a strategic approach to capitalize on emerging trends in the healthcare market - The mention of domestic replacements in medical devices suggests a shift towards local production and innovation, which could impact market competition and supply chains - The recovery in consumer healthcare points to potential growth areas as the market stabilizes post-pandemic

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a recent increase, reflecting a mixed performance over different time frames [1][2]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services rose by 0.39% to 13,367.74 points, with a trading volume of 14.635 billion yuan [1]. - Over the past month, the index has increased by 5.82%, while it has decreased by 2.05% over the last three months and by 2.72% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include: Mindray Medical (9.57%), Aier Eye Hospital (8.34%), United Imaging (7.63%), Aimeike (3.55%), Huatai Medical (3.28%), Yuyue Medical (2.88%), New Industry (2.81%), Meinian Onehealth (2.35%), Lepu Medical (2.07%), and Jiuan Medical (2.03%) [1]. Group 3: Market Segmentation - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.66%) and the Shanghai Stock Exchange (39.34%) [1]. - In terms of industry composition, medical devices account for 34.34%, medical consumables for 27.26%, in vitro diagnostics for 21.50%, and medical services for 16.90% [2]. Group 4: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern China Securities Index Healthcare Equipment and Services Link A, C, and I, Tianhong China Securities Index Healthcare Equipment and Services ETF, and others [2].

证券研究报告 | 公司点评报告 2025 年 05 月 07 日 惠泰医疗（688617.SH） 业绩符合预期，PFA 等新品获批进军房颤治疗领域 消费品/生物医药 公司发布 2024 年年度报告：2024 年实现营业收入 20.66 亿元，同比增长 25.18%；归母净利润 6.73 亿元，同比增长 26.08%；扣非归母净利润 6.43 亿 元，同比增长 37.29%。 其中，2024 年第四季度营业收入 5.41 亿元，同比增长 23.93%；归母净利润 1.45 亿元，同比增长 10.96%；扣非归母净利润 1.35 亿元，同比增长 24.69%。 同日，公司发布 2025 年第一季度报告：2025 年一季度实现营业收入 5.64 亿元， 同比增长 23.93%；归母净利润 1.83 亿元，同比增长 30.69%；扣非归母净利润 1.81 亿元，同比增长 32.23%。 ❑ 电生理手术量受益于集采持续增长，血管介入产品不断迭代入院率提升。 电生理业务：2024 年实现营业收入 4.40 亿元（yoy+19.73%），公司完成三 维电生理手术 15,000 余例，同比增长 50%。可调弯十极冠状窦导管在 ...

Group 1 - Major shareholders of *ST WanFang plan to reduce their holdings by up to 9,341,596 shares, accounting for 3% of the company's total share capital from May 27 to August 25, 2025 [1] - Shareholders of Airo Energy intend to reduce their holdings by up to 800,000 shares, 800,000 shares, and 1,600,000 shares, representing 0.50%, 0.50%, and 1% of the company's total share capital respectively during the same period [1] - Anner plans to reduce its holdings by up to 3,186,159 shares, which is 1.5% of the company's total share capital, from May 27 to August 26, 2025 [1] Group 2 - Shareholders of Chuhuan Technology plan to reduce their holdings by up to 2,395,605 shares, accounting for 3% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [1] - Major shareholder of Dalian Technology intends to reduce their holdings by up to 4,189,336 shares, which is 0.99% of the company's total share capital from May 27 to August 26, 2025 [2] - Dongwei Technology's board members plan to reduce their holdings by a total of 2,574,857 shares, representing 0.8629% of the company's total share capital during the same period [2] Group 3 - Gann Li Pharmaceutical's shareholder has completed a reduction of 6,010,622 shares, which is 1% of the company's total share capital from April 22 to April 30, 2025 [2] - Guanshi Technology's board members plan to reduce their holdings by up to 359,375 shares, accounting for 0.4891% of the company's total share capital from May 27 to August 26, 2025 [2] - Guoguang Electric's shareholder has completed a reduction of 1,625,751 shares, which is 1.5% of the company's total share capital from April 25 to April 30, 2025 [2] Group 4 - Haili Biological's major shareholder has completed a reduction of 13,113,244 shares, representing 2% of the company's total share capital from April 15 to April 22, 2025 [3] - Hengfeng Information's board member has completed a reduction of 198,717 shares, which is 0.1207% of the company's total share capital on April 28, 2025 [3] - Hongwei Technology's shareholder plans to reduce their holdings by up to 820,000 shares, accounting for 0.39% of the company's total share capital from May 12 to August 11, 2025 [3] Group 5 - Huatai Medical's vice president has completed a reduction of 29,943 shares, which is 0.0308% of the company's total share capital from April 28 to April 29, 2025 [4] - Jilin Carbon Valley's major shareholder has completed a reduction of 4,989,160 shares, representing 0.8490% of the company's total share capital from April 25 to April 29, 2025 [4] - Jiahua Technology's shareholder plans to reduce their holdings by up to 1,160,000 shares, accounting for 1.50% of the company's total share capital from May 28 to August 25, 2025 [4] Group 6 - Jiangbo Long's shareholder plans to reduce their holdings by up to 4,159,815 shares, which is 1% of the company's total share capital from May 27 to August 26, 2025 [5] - Jiangshan Co. plans to reduce its holdings in Jiangtian Chemical by 4,330,800 shares, accounting for 3% of its total share capital from May 27 to August 26, 2025 [5] - Kairun Co.'s major shareholder plans to reduce their holdings by up to 9,000,000 shares, representing 2.43% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [5] Group 7 - Lianqi Technology's shareholders plan to reduce their holdings by a total of 18,717,374 shares, which is 2.96% of the total share capital excluding repurchased shares from May 27 to August 26, 2025 [9] - Zhongke Information's board members have completed a reduction of 698,914 shares, representing 0.2358% of the company's total share capital [9] - Zhongshi Co.'s major shareholder plans to reduce their holdings by up to 1,800,000 shares, accounting for 1.1527% of the company's total share capital from May 27 to August 26, 2025 [10]

2025 年 04 月 29 日 公司点评 买入/维持 惠泰医疗(688617) 昨收盘:427.10 惠泰医疗点评报告：业绩持续高增长，PFA 有望贡献新增量 ◼ 走势比较 (20%) (8%) 4% 16% 28% 40% 24/4/29 24/7/10 24/9/20 24/12/1 25/2/11 25/4/24 ◼ 股票数据 总股本/流通(亿股) 0.97/0.97 总市值/流通(亿元) 414.64/414.64 12 个月内最高/最低价 (元) 569/303.52 相关研究报告 <<惠泰医疗点评报告：业绩基本符合 预期，看好集采下产品放量>>-- 2024-11-01 <<惠泰医疗点评报告：电生理手术量 保持强劲增长，业绩持续向好>>-- 2024-08-27 <<惠泰医疗点评报告：电生理手术量 增速强劲，血管介入新品迭出>>-- 2024-04-26 证券分析师：谭紫媚 电话：0755-83688830 E-MAIL：tanzm@tpyzq.com 分析师登记编号：S1190520090001 研究助理：李啸岩 电话：0755-83683312 E-MAIL：lixiaoyan@tpyzq. ...

2025 年 5 月 证券代码：688617 证券简称：惠泰医疗 深圳惠泰医疗器械股份有限公司 2024年年度股东大会 会议资料 | 深圳惠泰医疗器械股份有限公司 2024 年度财务决算报告 | 21 | | --- | --- | | 附件二 27 | | | 深圳惠泰医疗器械股份有限公司 2024 年度董事会工作报告 | 27 | | 附件三 31 | | 深圳惠泰医疗器械股份有限公司 2024 年年度股东大会会议资料 2024 年年度股东大会会议须知 为了维护全体股东的合法权益，确保公司股东大会的正常秩序和议事效率， 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国 证券法》（以下简称"《证券法》"）《上市公司股东会规则》以及《深圳惠泰 医疗器械股份有限公司章程》（以下简称"《公司章程》"）等相关规定，深圳 惠泰医疗器械股份有限公司（以下简称"公司"）特制订以下会议须知，请出席 股东大会的全体人员遵照执行。 | 年年度股东大会会议须知 2024 | 3 | | --- | --- | | 2024 年年度股东大会会议议程 | 4 | | 年年度股东大会议案 2024 | 6 | | ...

董监高持股的基本情况 本次减持计划实施前，深圳惠泰医疗器械股份有限公司（以下简称"公司"） 副总经理韩永贵先生（以下简称"减持主体"）持有公司股份 124,364 股，占公 司目前总股本 0.1281%。 减持计划的实施结果情况 公司于 2025 年 4 月 4 日在上海证券交易所官网（www.sse.com.cn）披露了《深 圳惠泰医疗器械股份有限公司部分高级管理人员减持股份计划公告》（公告编号： 2025-010）。公司副总经理韩永贵先生拟通过集中竞价、大宗交易方式减持，合 计不超过 30,000 股，即不超过公司总股本的 0.0309%。通过集中竞价交易的方式 减持的，在任意连续 90 个自然日内减持的股份总数不超过公司总股本的 1%，减 持期间为自本公告披露之日起 15 个交易日后的三个月内；通过大宗交易的方式 减持的，在任意连续 90 个自然日内减持的股份总数不超过公司总股本的 2%，减 持期间为自本公告披露之日起 15 个交易日后的三个月内。 近日，公司收到副总经理韩永贵先生出具的《减持股份结果告知函》，截至 2025 年 4 月 29 日，韩永贵先生已通过集中竞价交易方式减持公司股份 29,94 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1]. Core Views - The company continues to experience rapid growth, with a significant increase in electrophysiology procedures and potential growth in peripheral products due to centralized procurement [1][5]. - The target price has been adjusted to 504.27, reflecting a 40% upside from the current price of 433.06 [1][5]. Financial Summary - For 2024, the company is projected to achieve revenue of 2,066 million, representing a growth of 25.2%, and a net profit of 673 million, reflecting a growth of 26.1% [3][5]. - The first quarter of 2025 is expected to show revenue of 5.64 billion, a year-on-year increase of 23.93%, and a net profit of 1.83 billion, up 30.69% [5]. - The earnings per share (EPS) estimates have been adjusted to 9.34 for 2025 and 15.89 for 2027 [5]. Operational Highlights - The company has seen a 50% increase in three-dimensional electrophysiology procedures, with over 15,000 procedures completed in 2024 [5]. - The company’s electrophysiology revenue is expected to reach 4.4 billion, a growth of 19.73% [5]. - The company has successfully launched key products in the electrophysiology market, including AForcePlus catheters and a cardiac pulsed field ablation device [5]. Market Position - The company has expanded its market presence, with over 1,360 hospitals now using its electrophysiology products, and a significant increase in the number of hospitals adopting its coronary and peripheral products [5]. - International revenue is projected to grow by 19.75%, with a notable 45.88% increase in self-branded products in key markets [5].